Skip to content


Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Sanofi investigating payments in Africa, Middle East

French pharma Sanofi is investigating possible illegal payments in the Middle East and Africa from 2007 to 2012 following allegations from an anonymous whistleblower.

Sanofi said Monday it has self reported the allegations to the U.S. Justice Department and the Securities and Exchange Commission.

The company said it hired New York law firm Weil Gotshal to investigate the allegations.

“At this stage, it is too early to draw conclusions,” a company spokesman told the Wall Street Journal. “Sanofi takes these allegations seriously.”and expects the probe to take “some time,” given the alleged activity dates back several years.

Last month, a court in China fined UK pharma giant GlaxoSmithKline $490 million following a conviction for bribery.

GSK’s former head of China operations, Mark Reilly, was given a three-year prison sentence that was suspended.

China authorities in July 2013 accused GSK of paying $490 million in bribes to health officials and doctors to boost sales. Prosecutors said GSK had used 700 travel agents to deliver the illegal payments since 2007.

In late 2012, Indianapolis-based Eli Lilly and Company resolved FCPA civil charges brought by the SEC for alleged bribes to government officials in Russia, Brazil, China, and Poland.

Lilly agreed to pay $29.4 million without admitting or denying the SEC’s allegations.

In the Sanofi probe, the whistleblower alleged in emails that employees of a unit in Kenya bribed medical professionals, the Wall Street Journal said.

“Sanofi paid for influential medical professionals to attend conferences, many of which were abroad, and gave them cash and gifts at its own events to win business, the emails allege.”

Sanofi trades on the NYSE under the symbol SNY.


Richard L. Cassin is the publisher and editor of the FCPA Blog. He can be contacted here.

Share this post


Comments are closed for this article!